Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18868428 | 0.93 | ALDH1A1 (0.61) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL22664776 | 0.92 | ALDH1A1 (0.82) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL392625 | 0.89 | ALDH1A1 (0.82) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL21485020 | 0.85 | ALDH1A1 (0.73) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL10133036 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL10133256 | 0.84 | ALDH1A1 (0.75) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL3838048 | 0.84 | ALDH1A1 (0.75) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL14758329 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNARAB9AL3MBTL1CA1 | |
| SCHEMBL12643755 | 0.84 | SMN1; SMN2 (0.68) | LMNAGAAMAPTKMT2AMEN1 | |
| SCHEMBL11625886 | 0.83 | ALDH1A1 (0.59) | ALDH1A1LMNARAB9AL3MBTL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282764-A1 | IMIDAZOLE HETEROCYCLE BASED COMPOUNDS AND METHODS OF TREATING CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2025-09-11 | — | — | US | disclosed |
| US-12258321-B1 | Aryl-1,2,3-triazole compounds, pharmaceutical composition thereof and method for treatment of breast cancer | University of Jeddah (SA) | 2025-03-25 | — | — | US | disclosed |
| US-11325885-B2 | Method for treating stomach cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-10 | — | — | US | disclosed |
| US-11312680-B2 | Method for treating a patient having a colon cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-11220485-B2 | Chemotherapeutic oxazolone derivatives and pharmaceutical compositions thereof | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-11 | — | — | US | disclosed |
| US-11214537-B2 | Method for making anti-cancer compounds | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-04 | — | — | US | disclosed |
| US-11214537-B2 | Method for making anti-cancer compounds | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-04 | — | — | US | disclosed |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-23 | — | — | US | disclosed |
| US-20210380526-A1 | METHOD FOR TREATING STOMACH CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-09 | — | — | US | disclosed |
| US-11180458-B2 | Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-11-23 | — | — | US | disclosed |
| US-20200385336-A1 | CYTOTOXIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2020-12-10 | — | — | US | disclosed |
| US-20200385337-A1 | AMIDE GROUP-CONTAINING COMPOUNDS AND USE FOR CANCER TREATMENT | KING ABDULAZIZ UNIVERSITY (SA) | 2020-12-10 | — | — | US | disclosed |
| US-20200385337-A1 | AMIDE GROUP-CONTAINING COMPOUNDS AND USE FOR CANCER TREATMENT | KING ABDULAZIZ UNIVERSITY (SA) | 2020-12-10 | — | — | US | disclosed |
| US-10844007-B1 | Amide group-containing compounds and use for cancer treatment | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-24 | — | — | US | disclosed |
| US-10844007-B1 | Amide group-containing compounds and use for cancer treatment | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-24 | — | — | US | disclosed |
| US-10844022-B1 | Pharmaceutical composition and method of treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-24 | — | — | US | disclosed |
| EP-0713483-B1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-6030985-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 2000-02-29 | — | — | US | disclosed |
| US-5807885-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 1998-09-15 | — | — | US | disclosed |
| WO-1995005363-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRA AKTIEBOLAG (SE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380526-A1 | METHOD FOR TREATING STOMACH CANCER | TUBB, TUBB1, TUBA1C | ALDH1A1 3409/4885LMNA 2474/4885RAB9A 2126/4885 |
| US-20250282764-A1 | IMIDAZOLE HETEROCYCLE BASED COMPOUNDS AND METHODS OF TREATING CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK2, CDK13 | ALDH1A1 1214/4885LMNA 1860/4885RAB9A 2185/4885 |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | TUBB1, TUBA1C, TUBB | ALDH1A1 2594/4885LMNA 2017/4885RAB9A 2753/4885 |
| US-20200385336-A1 | CYTOTOXIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATING CANCER | SRC, MCL1, LYN | ALDH1A1 3413/4885LMNA 2153/4885RAB9A 1714/4885 |
| US-11180458-B2 | Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer | PLK2, SRC, TUBB | ALDH1A1 2323/4885LMNA 922/4885RAB9A 1849/4885 |
| US-11214537-B2 | Method for making anti-cancer compounds | MCL1, TUBB, TUBB1 | ALDH1A1 3075/4885LMNA 1640/4885RAB9A 2265/4885 |
| US-11312680-B2 | Method for treating a patient having a colon cancer | TUBB1, TUBA1C, TUBB | ALDH1A1 2594/4885LMNA 2017/4885RAB9A 2753/4885 |
| US-10844007-B1 | Amide group-containing compounds and use for cancer treatment | SRC, TUBB, TUBB1 | ALDH1A1 3615/4885LMNA 3112/4885RAB9A 1721/4885 |
| US-11325885-B2 | Method for treating stomach cancer | TUBB, TUBB1, TUBA1C | ALDH1A1 3409/4885LMNA 2474/4885RAB9A 2126/4885 |
| US-11220485-B2 | Chemotherapeutic oxazolone derivatives and pharmaceutical compositions thereof | PLK2, SRC, MCL1 | ALDH1A1 1635/4885LMNA 1972/4885RAB9A 4082/4885 |
| US-10844022-B1 | Pharmaceutical composition and method of treating cancer | PLK2, SRC, SRMS | ALDH1A1 2684/4885LMNA 908/4885RAB9A 2419/4885 |
| US-20200385337-A1 | AMIDE GROUP-CONTAINING COMPOUNDS AND USE FOR CANCER TREATMENT | SRC, TUBB, TUBB1 | ALDH1A1 3615/4885LMNA 3112/4885RAB9A 1721/4885 |
| US-12258321-B1 | Aryl-1,2,3-triazole compounds, pharmaceutical composition thereof and method for treatment of breast cancer | MCL1, BCL2, BCL2A1 | ALDH1A1 1122/4885LMNA 1804/4885RAB9A 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.